^
    Back
    Association details:
    Biomarker:SAMHD1 expression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Platinum alkylating agent
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    EACR 2021
    Title:

    SAMHD1 confers resistance to platinum-based drugs through modification of DNA damage response

    Published date:
    05/28/2021
    Excerpt:
    In NSCLC and OC patients, high SAMHD1 expression was associated with shorter time to progression and overall survival (p=.004, p=.014 and p=.003, p=.06, respectively), as well as with lower response in NSCLC (p=.047), strongly validating SAMHD1 as a biomarker in cancer.
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    EACR 2021
    Title:

    Prognostic and predictive value of SAMHD1 espression in solid tumors

    Published date:
    05/28/2021
    Excerpt:
    ...explored the potential rol of SAMHD1 expression in advanced non-small cell lung (NSCLC), ovarian (OC) and breast cancer (BC) patients (p)...16 NSCLC p treated with platinum-containing regimens...SAMHD1 positivity was associated with shorter time to progression (TTP), overall survival (OS), and overall survival from de diagnosis of cancer (OSDC) for NSLC p (p=.004, p=.014, and p=.004, respectively).